S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

$3.38
-0.02 (-0.59%)
(As of 04/17/2024 ET)
Today's Range
$3.20
$3.49
50-Day Range
$1.60
$4.20
52-Week Range
$1.28
$4.27
Volume
158,985 shs
Average Volume
124,871 shs
Market Capitalization
$209.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Galectin Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
225.4% Upside
$11.00 Price Target
Short Interest
Bearish
5.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Galectin Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.66) to ($1.59) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

791st out of 914 stocks

Pharmaceutical Preparations Industry

348th out of 406 stocks

GALT stock logo

About Galectin Therapeutics Stock (NASDAQ:GALT)

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Stock Price History

GALT Stock News Headlines

Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
GALT Galectin Therapeutics Inc.
Galectin Therapeutics GAAP EPS of -$0.24
Galectin Therapeutics: Q3 Earnings Insights
See More Headlines
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/17/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GALT
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.01) per share

Miscellaneous

Free Float
29,281,000
Market Cap
$204.27 million
Optionable
Optionable
Beta
0.84
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Joel Lewis (Age 54)
    President, CEO & Director
    Comp: $907.72k
  • Mr. Jack W. Callicutt CPA (Age 57)
    CFO, Treasurer & Corporate Secretary
    Comp: $521.47k
  • Dr. Pol F. Boudes M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $730.33k
  • Robert Tritt
    General Counsel
  • Mr. Jeff Katstra
    Head of CMC & Pharmaceutical Development
  • Ms. Beth Knowles
    Executive Assistant & Officer Manager

GALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GALT shares.
View GALT analyst ratings
or view top-rated stocks.

What is Galectin Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price objectives for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 225.4% from the stock's current price.
View analysts price targets for GALT
or view top-rated stocks among Wall Street analysts.

How have GALT shares performed in 2024?

Galectin Therapeutics' stock was trading at $1.66 on January 1st, 2024. Since then, GALT shares have increased by 103.6% and is now trading at $3.38.
View the best growth stocks for 2024 here
.

Are investors shorting Galectin Therapeutics?

Galectin Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,250,000 shares, an increase of 5.1% from the March 15th total of 2,140,000 shares. Based on an average trading volume of 105,800 shares, the short-interest ratio is presently 21.3 days. Currently, 5.3% of the company's stock are sold short.
View Galectin Therapeutics' Short Interest
.

When is Galectin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our GALT earnings forecast
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04.

What ETF holds Galectin Therapeutics' stock?

Horizon Kinetics Medical ETF holds 53,742 shares of GALT stock, representing 1.17% of its portfolio.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GALT) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners